-
PDLI Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
PDL Biopharma (PDLI)
Company Profile
Quarter (USD) | Dec 20 | Sep 20 | Jun 20 | Mar 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 126.84 mm | 126.84 mm | 126.84 mm | 126.84 mm | 126.84 mm | |
Cash burn (monthly) | (no burn) | 3.51 mm | 4.13 mm | 24.50 mm | 7.37 mm | |
Cash used (since last report) | n/a | 172.94 mm | 203.30 mm | 1.21 bn | 363.07 mm | |
Cash remaining | n/a | -46.09 mm | -76.46 mm | -1.08 bn | -236.23 mm | |
Runway (months of cash) | n/a | -13.1 | -18.5 | -44.1 | -32.0 |
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 3 |
Closed positions | 2 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 42.56 mm |
Total shares | 4.70 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Engine Capital | 4.52 mm | $14.58 mm |
HWC Hancock Whitney Corporation - 6 | 128.40 k | $0.00 |
Argent Trust | 41.41 k | $0.00 |
Diversified Trust | 11.03 k | $26.47 mm |
Rhumbline Advisers | 612.00 | $1.51 mm |